Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ADX-914 in Healthy Volunteers
NCT04485481Phase 1Completed
- Sponsor
- Q32 Bio
- Start
- Sep 2020
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bempikibart in alopecia areata and atopic dermatitis (AD) (4 arms), sponsored by Q32 Bio. Primary endpoints: Number of subjects with adverse events, Number of subjects with Physical exam findings and 4 more. Started Sep 2020; status: completed.
02
Drugs
bempikibart
03
Conditions
alopecia areataatopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04485481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04485481.